Zoetis Inc.

Executive Summary

HOLD, Low conviction. ZTS rates a HOLD at Low conviction. The stock has already reset hard, down 53.1% from the 52-week high to $73.54, and the valuation looks optically cheap at 12.39x P/E versus peers at 28.9x, but management just cut FY26 guidance to $6.15 to $6.25 of adjusted EPS and explicitly said U.S. volume and share pressure are assumed to continue. The setup is no longer expensive, yet the earnings base is still moving down.

Investment Thesis

The case for owning ZTS at $73.54 starts with one fact: the market has already punished the stock hard. At -53.1% from the 52-week high and trading at 12.39x P/E, this is no longer a premium compounder priced for perfection. It is a reset story. That matters because Zoetis still runs a business with 36.6% FY2025 operating margins, 26.9% net margins, almost no leverage, and enough cash generation to keep funding R&D, commercial support, and selective acquisitions.

The issue is that the stock is not just cheap because of sentiment. It is cheap because the earnings algorithm broke. Q2 FY26 exposed real weakness in the core U.S. Companion Animal franchise, with -11% growth there and -16% in dermatology. Management did not hide from it. They cut FY26 revenue guidance to $9.12B to $9.32B and adjusted EPS to $6.15 to $6.25, while saying July showed no stabilization. Even worse, the company admitted that heavier promotions are now needed in derm and parasiticides, and that future volume and share will remain under pressure. That is not the language of a business about to snap back next quarter.

The bullish angle depends on three things. First, the pressure has to stay contained rather than spread. Livestock at +11%, diagnostics at +12%, and international at +6% show the franchise is not broadly impaired. Second, the margin base has to stop sliding. Q2 EBITDA margin of 37.6% is still healthy, but the 640 bps YoY decline cannot become a pattern. Third, pipeline and ecosystem moves need to matter, especially long-acting Cytopoint, OmniMax, and the VitalRADS diagnostics expansion, because those are the clearest routes to restoring differentiation beyond discounts.

What keeps conviction low is simple: this is still a falling-earnings story until proven otherwise. The stock may very well bottom before fundamentals do, but the market is unlikely to pay materially more than a depressed multiple until U.S. Companion Animal stops deteriorating. That leaves ZTS in the awkward middle. Too cheap to dismiss outright, not stable enough to call a clean buy.

Key Metrics

Financial Strength

Financial strength is not the problem here. Zoetis carries almost no leverage, with Debt/EBITDA 0.05 and Debt/Equity 0.06, while still producing healthy margins and positive free cash flow. The concern is quality of the earnings slope, not solvency. Margin compression in Q2 was meaningful, and shareholder returns currently exceed FCF, so the balance sheet gives management flexibility, but it does not erase the need to stabilize the operating model.

Competitive Position

Zoetis still has a durable moat built on product breadth across companion animal, livestock, and diagnostics, plus entrenched veterinary relationships and a scale advantage in commercialization. That moat has weakened at the margin because dermatology and parasiticides now require heavier promotions to defend volume and share, which means brand power is not as clean as it looked in 2024. Durability over the next 3 to 5 years will depend less on legacy pricing power and more on whether Zoetis can tie therapeutics, diagnostics, and workflow tools into a stickier clinical ecosystem.

Management & Guidance

Current guidance is appropriately cautious and more believable precisely because it was cut hard. Management now expects FY26 revenue of $9.12B to $9.32B and adjusted EPS of $6.15 to $6.25, after acknowledging that Q2 "fell short of our expectations" and that July showed no stabilization. Given the recent track record of 7 beats in 8 quarters but one notable -4.4% miss in May 2026, guidance should be treated as a reset base, not a conservative floor. Credibility is intact enough to trust the numbers directionally, but not strong enough to assume upside surprise.

Segment Analysis

• Companion Animal (Majority of revenue, exact FY mix not provided): Current pressure is concentrated here, with U.S. Companion Animal -11% in Q2 and dermatology -16%, making this the swing factor for recovery
• Livestock (Meaningful secondary segment, exact FY mix not provided): Q2 growth of +11% was strong, helped by U.S. cattle demand and New World screwworm-related parasiticide demand
• Diagnostics (Smaller but strategically important, exact FY mix not provided): Q2 growth of +12% and the VitalRADS acquisition expand the ecosystem into teleradiology and virtual reference lab capabilities
• International (Exact geographic mix not provided): +6% revenue growth in Q2 with broad emerging-market strength is offsetting weaker U.S. trends
• United States (Exact geographic mix not provided): This is the problem area, with lower clinic visits, affordability pressure, and heavier competition driving the FY26 guide cut

Capital Allocation

Capital allocation is mixed. The company generated $0.8B of FCF with $0.2B of capex, but returned $1.2B via buybacks and $0.4B via dividends, which exceeds current FCF and is harder to defend while guidance is falling. The balance sheet can support it because leverage is extremely low, and the VitalRADS deal shows management is still willing to fund targeted capability expansion rather than rely only on repurchases.

Management Execution & Track Record

Management was highly credible in late 2024, then lost some of that standing in 2026. On the 2024 Q3 call, the company guided FY24 revenue to $9.2B to $9.3B, operational growth to 10% to 11%, and adjusted EPS to $5.86 to $5.92, while describing balanced double-digit growth and saying 2025 trends in OA, dermatology, Simparica, and alternative channels remained positive. By FY2025, revenue reached $9.5B and EPS $6.03, so the broad growth algorithm initially held. The problem is what happened after: by Q2 2026, Zoetis cut FY26 revenue guidance to $9.12B to $9.32B and adjusted EPS to $6.15 to $6.25, with organic operational revenue growth of -3% to -1% and adjusted net income growth of -9% to -5%. Q2 FY26 revenue was flat reported and -1% organic, EBITDA margin fell to 37.6% from 44.5% in 2024 Q3, and management acknowledged the business "fell short of our expectations." The earnings beat/miss history is still decent, with 7 beats in the last 8 reports, but the latest guidance reset and share pressure mean management now deserves only moderate credibility, not the premium it had two years ago.

Positioning & Flows

Ownership is very concentrated, with the top three institutions at 90.9%, which can stabilize the base but also reduce the marginal buyer pool when fundamentals break. Short interest at 21.35M shares, or 5.10% of float, with 3.3 days-to-cover and a 13.6% increase, shows skepticism is building but not at squeeze levels. Near-dated options positioning is unfavorable, with a negative gamma regime and zero-gamma at $74.22, almost exactly spot, which suggests weak technical support rather than a forced upside setup.

Bull Case

• Profitability remains high even in a down year, with FY2025 operating margin at 36.6% and Q2 FY26 EBITDA margin still 37.6% despite a 640 bps YoY decline
• Balance sheet risk is minimal, with Debt/Equity 0.06, Debt/EBITDA 0.05, and a 3.08 current ratio, giving Zoetis room to defend R&D and commercial spend through the downturn
• Parts of the portfolio are still growing, with International revenue +6%, Livestock +11%, and Diagnostics +12% in Q2, plus pipeline milestones from long-acting Cytopoint expected later this year and OmniMax validation by year-end
• The stock has already derated sharply, now 31.7% below the 200-day average and 70.2% below the 5-year high, which lowers valuation risk if operations simply stop worsening

Bear Case

• Management cut FY26 revenue guidance to $9.12B to $9.32B, implying organic operational revenue growth of -3% to -1%, after Q2 revenue was flat reported and -1% organic
• Competitive pressure is active, not theoretical: Zoetis said gross-to-net promotions accelerated in dermatology and parasiticides, and CEO Kristin Peck said, "we think that our volume and our market share will continue to be under pressure. That is assumed."
• Q2 margin deterioration was material, with EBITDA margin down to 37.6%, off 640 bps YoY and 390 bps versus Q1, showing that price and mix are no longer carrying the model
• Execution confidence has softened after a recent miss, with 2026-05-07 EPS at 1.53 vs 1.60, a -4.4% miss, and call sentiment on the latest quarter at 31/100

Valuation & Price Target

Engine price target $90.61 (+23.2% vs current), Low confidence.

• P/E Multiple: $177.12 (14% weight)
• PEG (growth-adjusted): $54.72 (20% weight)
• P/S Multiple: $65.51 (20% weight)
• Quality-adjusted: $76.48 (20% weight)
• DCF: $193.45 (3% weight)

The quant baseline of HOLD is the right anchor here. The engine's $90.61 target implies 23.2% upside, but confidence is explicitly Low, and the blended methods are all over the map, from $54.72 on PEG to $193.45 on DCF, with a peer set carrying wide dispersion of 4.8x on P/E. That spread reflects the core issue: ZTS looks statistically cheap at 12.39x P/E, yet the business just moved to negative organic growth and lower margins. The sell-side consensus of Strong Buy is low-signal context only and is less persuasive than management's own FY26 cut, especially with U.S. Companion Animal at -11% and management assuming ongoing share pressure. A more bullish call would require evidence that the earnings base has stabilized, not just that the stock is down a lot.

Risk Assessment

Risk score 50/100 (Moderate). The biggest risk is that U.S. Companion Animal, already -11% in Q2, stays weak into 2027 and turns the current FY26 EPS guide of $6.15 to $6.25 into another reset.

The Bottom Line

Rated HOLD, Low conviction. ZTS is no longer expensive, and the balance sheet plus franchise quality make it dangerous to be outright bearish after a 53.1% drawdown from the high. But the company just shifted from a growth story to a stabilization story, and management is telling investors that U.S. volume and share pressure are still ahead. The stock becomes more attractive on evidence that Companion Animal has bottomed and that margin erosion is moderating. A move to BUY would require proof of stabilization in U.S. Companion Animal and cleaner follow-through on FY26 guidance.